• Je něco špatně v tomto záznamu ?

Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout

A. Kvasnička, D. Friedecký, B. Piskláková, J. Rozhon, K. Pavelka, B. Stibůrková

. 2025 ; 159 (-) : 107495. [pub] 20250415

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015479

Gout and hyperuricemia increase cardiovascular disease risk, highlighting the need for improved risk stratification. In this pilot study, we evaluated the Coronary Event Risk Test (CERT) in 94 hyperuricemic and 196 gout patients, and 53 controls. Plasma ceramides were determined by liquid chromatography-mass spectrometry. Elevated CERT scores (≥7) occurred in 11.7 % (2-fold increase) of hyperuricemic and 31.12 % (5.5-fold increase) of gout patients compared to controls. Additionally, both hyperuricemic and gout patients with increased CERT also exhibited higher levels of inflammation and atherogenic index of plasma, both of which were significantly associated with CERT. Incorporating CERT into routine care may enhance risk stratification and guide targeted interventions in this patient population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015479
003      
CZ-PrNML
005      
20250731091017.0
007      
ta
008      
250708e20250415xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vph.2025.107495 $2 doi
035    __
$a (PubMed)40239856
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kvasnička, Aleš $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
245    10
$a Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout / $c A. Kvasnička, D. Friedecký, B. Piskláková, J. Rozhon, K. Pavelka, B. Stibůrková
520    9_
$a Gout and hyperuricemia increase cardiovascular disease risk, highlighting the need for improved risk stratification. In this pilot study, we evaluated the Coronary Event Risk Test (CERT) in 94 hyperuricemic and 196 gout patients, and 53 controls. Plasma ceramides were determined by liquid chromatography-mass spectrometry. Elevated CERT scores (≥7) occurred in 11.7 % (2-fold increase) of hyperuricemic and 31.12 % (5.5-fold increase) of gout patients compared to controls. Additionally, both hyperuricemic and gout patients with increased CERT also exhibited higher levels of inflammation and atherogenic index of plasma, both of which were significantly associated with CERT. Incorporating CERT into routine care may enhance risk stratification and guide targeted interventions in this patient population.
650    _2
$a lidé $7 D006801
650    12
$a hyperurikemie $x krev $x diagnóza $x komplikace $7 D033461
650    12
$a dna (nemoc) $x krev $x diagnóza $x komplikace $7 D006073
650    _2
$a mužské pohlaví $7 D008297
650    12
$a ceramidy $x krev $7 D002518
650    _2
$a lidé středního věku $7 D008875
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a pilotní projekty $7 D010865
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a senioři $7 D000368
650    12
$a kardiovaskulární nemoci $x diagnóza $x krev $x etiologie $x epidemiologie $7 D002318
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a rizikové faktory kardiovaskulárních chorob $7 D000082742
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a metody pro podporu rozhodování $7 D003661
650    12
$a kyselina močová $x krev $7 D014527
650    _2
$a chromatografie kapalinová $7 D002853
650    _2
$a prognóza $7 D011379
650    _2
$a dospělí $7 D000328
655    _2
$a časopisecké články $7 D016428
700    1_
$a Friedecký, David $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
700    1_
$a Piskláková, Barbora $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
700    1_
$a Rozhon, Jakub $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Stibůrková, Blanka $u Institute of Rheumatology, Prague, Czech Republic; Department of Pediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic. Electronic address: stiburkova@revma.cz
773    0_
$w MED00008593 $t Vascular pharmacology $x 1879-3649 $g Roč. 159 (20250415), s. 107495
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40239856 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091012 $b ABA008
999    __
$a ok $b bmc $g 2366363 $s 1252604
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 159 $c - $d 107495 $e 20250415 $i 1879-3649 $m Vascular pharmacology $n Vascul Pharmacol $x MED00008593
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace